Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most frequently used drugs, either on prescription or over-thecounter (OTC). Their daily dosage is based on randomised controlled trials and an empirical clinical assessment of their efficacy and toxicity that allows dose adjustment. The individual response can however be altered by environmental and genetic pharmacokinetic and pharmacodynamic factors. This review summarizes the available pharmacogenetic data that explains part of the variability in response and occurrence of adverse drug reactions to NSAIDs treatment, with a thorough focus on CYP2C9, uridine diphosphate glucuronosyltransferases (UGTs) and cyclooxygenases (COX1 and COX2). Other polymorphisms that are currently being studied and could also explain the interindividual variability in the efficacy and safety of NSAIDs will also be considered.
Keywords: COX, CYP2C8, CYP2C9, genetic polymorphism, NSAIDs, PTGS, UDP glucuronsyltransferases, UGT.
Current Drug Metabolism
Title:Prediction by Pharmacogenetics of Safety and Efficacy of Non-Steroidal Anti- Inflammatory Drugs: A Review
Volume: 15 Issue: 3
Author(s): Victoria Rollason, Caroline Flora Samer, Youssef Daali and Jules Alexandre Desmeules
Affiliation:
Keywords: COX, CYP2C8, CYP2C9, genetic polymorphism, NSAIDs, PTGS, UDP glucuronsyltransferases, UGT.
Abstract: Non-steroidal anti-inflammatory drugs (NSAIDs) are the most frequently used drugs, either on prescription or over-thecounter (OTC). Their daily dosage is based on randomised controlled trials and an empirical clinical assessment of their efficacy and toxicity that allows dose adjustment. The individual response can however be altered by environmental and genetic pharmacokinetic and pharmacodynamic factors. This review summarizes the available pharmacogenetic data that explains part of the variability in response and occurrence of adverse drug reactions to NSAIDs treatment, with a thorough focus on CYP2C9, uridine diphosphate glucuronosyltransferases (UGTs) and cyclooxygenases (COX1 and COX2). Other polymorphisms that are currently being studied and could also explain the interindividual variability in the efficacy and safety of NSAIDs will also be considered.
Export Options
About this article
Cite this article as:
Rollason Victoria, Samer Flora Caroline, Daali Youssef and Desmeules Alexandre Jules, Prediction by Pharmacogenetics of Safety and Efficacy of Non-Steroidal Anti- Inflammatory Drugs: A Review, Current Drug Metabolism 2014; 15 (3) . https://dx.doi.org/10.2174/1389200215666140202214454
DOI https://dx.doi.org/10.2174/1389200215666140202214454 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
Call for Papers in Thematic Issues
Impact of brain tissue binding and plasma protein binding of drugs in DMPK
The impression of brain tissue binding (BTB) or plasma protein binding (PPB) in Drug Metabolism and Pharmacokinetics is critical to understanding the distribution, efficacy, and potential toxicity of drugs that target the central nervous system (CNS). BTB and high PPB influence the distribution of drugs in the body and their ...read more
Metabolism-Mediated Xenobiotic Toxicity
Considering the potent modulation of biotransformation enzyme expression and activities by various therapeutic drugs and environmental chemicals, and the commonly combined exposure of humans to both drugs and the ever increasing environmental pollutants simultaneously, knowledge about the combined toxic effects by modulating biotransformation enzymes, such as P450s, UDP- glucuronosyltransferases, and ...read more
Safety evaluation of vaccine combination
Vaccine combination safety evaluation is a critical field within immunology and public health that focuses on assessing the safety and efficacy of combining different vaccines to maximize protection against various diseases while minimizing potential adverse effects. This process is significant because it ensures that vaccines can be administered together without ...read more
Therapeutic drug monitoring in clinical applications
Therapeutic Drug Monitoring (TDM) is a special issue focusing on the monitoring of drug concentrations in clinical therapy, aiming to optimize drug therapy, reduce drug interactions and ensure patient safety through quantitative analysis of drug concentrations in patient's; body fluids. TDM is of great significance in the current medical field, ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The ONTARGET Trial Programme: Facts and Lessons
Current Hypertension Reviews Immediate and Late Adverse Reactions to Iodinated Contrast Media: A Pharmacological Point of View
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of Inflammation and Allergy in Acute Coronary Syndromes
Inflammation & Allergy - Drug Targets (Discontinued) Peptides As Therapeutics with Enhanced Bioactivity
Current Medicinal Chemistry Prevention of Bacterial Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets Aging and Remodeling During Healing of the Wounded Heart: Current Therapies and Novel Drug Targets
Current Drug Targets Difficulties in Describing Allergic Disease Modulation by Pre-, Pro- and Synbiotics
Current Pharmaceutical Design Aliskiren: A New Drug for an Old Problem
Cardiovascular & Hematological Agents in Medicinal Chemistry Seasonal Allergic Rhinitis
Recent Patents on Inflammation & Allergy Drug Discovery The Validity of Chemical Analytical Methods by the Example of the Heparin Product Recall
Current Pharmaceutical Analysis The Tumor Necrosis Factor-Derived TIP Peptide: A Potential Anti-Edema Drug
Letters in Drug Design & Discovery Interrelationships with Metabolic Syndrome, Obesity and Cardiovascular Risk
Current Vascular Pharmacology Neuroprotective Methodologies of Co-Enzyme Q10 Mediated Brain Hemorrhagic Treatment: Clinical and Pre-Clinical Findings
CNS & Neurological Disorders - Drug Targets Drug-Induced Aseptic Meningitis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Target Product Selection - Where Can Molecular Pharming Make the Difference?
Current Pharmaceutical Design PF-04886847 (an Inhibitor of Plasma Kallikrein) Attenuates Inflammatory Mediators and Activation of Blood Coagulation in Rat Model of Lipopolysaccharide (LPS) - Induced Sepsis
Cardiovascular & Hematological Agents in Medicinal Chemistry Cross-Reactive Reactions to Nonsteroidal Anti-Inflammatory Drugs
Current Pharmaceutical Design Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450
Current Drug Metabolism Acute and Long-Term Effects of Cannabis Use: A Review
Current Pharmaceutical Design Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery